Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.

O'Brien MER, Sarker D, Bhosle J, Thillai K, Yap TA, Uttenreuther-Fischer M, Pemberton K, Jin X, Wiebe S, de Bono J, Spicer J.

Cancer Chemother Pharmacol. 2018 Aug 7. doi: 10.1007/s00280-018-3661-1. [Epub ahead of print]

PMID:
30088048
2.

Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE.

Gaspar N, Marshall LV, Binner D, Herold R, Rousseau R, Blanc P, Capdeville R, Carleer J, Copland C, Kerloeguen Y, Norga K, Pacaud L, Sevaux MA, Spadoni C, Sterba J, Ligas F, Taube T, Uttenreuther-Fischer M, Chioato S, O'Connell MA, Geoerger B, Blay JY, Soria JC, Kaye S, Wulff B, Brugières L, Vassal G, Pearson ADJ; Members of Working Group 1 of the Paediatric Platform of ACCELERATE.

Ann Oncol. 2018 Mar 1;29(3):766-771. doi: 10.1093/annonc/mdy002. No abstract available.

3.

Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.

Bahleda R, Varga A, Bergé Y, Soria JC, Schnell D, Tschoepe I, Uttenreuther-Fischer M, Delord JP.

Br J Cancer. 2018 Feb 6;118(3):344-352. doi: 10.1038/bjc.2017.436. Epub 2018 Jan 16.

PMID:
29337963
4.

Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.

Goh G, Schmid R, Guiver K, Arpornwirat W, Chitapanarux I, Ganju V, Im SA, Kim SB, Dechaphunkul A, Maneechavakajorn J, Spector N, Yau T, Afrit M, Ahmed SB, Johnston SR, Gibson N, Uttenreuther-Fischer M, Herrero J, Swanton C.

PLoS Med. 2016 Dec 6;13(12):e1002136. doi: 10.1371/journal.pmed.1002136. eCollection 2016 Dec.

5.

A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.

Spicer J, Irshad S, Ang JE, Enting D, Kristeleit R, Uttenreuther-Fischer M, Pemberton K, Pelling K, Schnell D, de Bono J.

Cancer Chemother Pharmacol. 2017 Jan;79(1):17-27. doi: 10.1007/s00280-016-3189-1. Epub 2016 Nov 21.

6.

Implementation of mechanism of action biology-driven early drug development for children with cancer.

Pearson AD, Herold R, Rousseau R, Copland C, Bradley-Garelik B, Binner D, Capdeville R, Caron H, Carleer J, Chesler L, Geoerger B, Kearns P, Marshall LV, Pfister SM, Schleiermacher G, Skolnik J, Spadoni C, Sterba J, van den Berg H, Uttenreuther-Fischer M, Witt O, Norga K, Vassal G; Members of Working Group 1 of the Paediatric Platform of ACCELERATE.

Eur J Cancer. 2016 Jul;62:124-31. doi: 10.1016/j.ejca.2016.04.001. Epub 2016 May 31. Review.

PMID:
27258969
7.

A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole.

Gunzer K, Joly F, Ferrero JM, Gligorov J, de Mont-Serrat H, Uttenreuther-Fischer M, Pelling K, Wind S, Bousquet G, Misset JL.

Springerplus. 2016 Jan 19;5:45. doi: 10.1186/s40064-015-1601-7. eCollection 2016.

8.

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.

Harbeck N, Huang CS, Hurvitz S, Yeh DC, Shao Z, Im SA, Jung KH, Shen K, Ro J, Jassem J, Zhang Q, Im YH, Wojtukiewicz M, Sun Q, Chen SC, Goeldner RG, Uttenreuther-Fischer M, Xu B, Piccart-Gebhart M; LUX-Breast 1 study group.

Lancet Oncol. 2016 Mar;17(3):357-66. doi: 10.1016/S1470-2045(15)00540-9. Epub 2016 Jan 26.

PMID:
26822398
9.

A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.

Suder A, Ang JE, Kyle F, Harris D, Rudman S, Kristeleit R, Solca F, Uttenreuther-Fischer M, Pemberton K, Pelling K, Schnell D, de Bono J, Spicer J.

Eur J Cancer. 2015 Nov;51(16):2275-84. doi: 10.1016/j.ejca.2015.07.041. Epub 2015 Aug 18.

PMID:
26296295
10.

Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.

Mukai H, Masuda N, Ishiguro H, Mitsuma A, Shibata T, Yamamura J, Toi M, Watabe A, Sarashina A, Uttenreuther-Fischer M, Ando Y.

Cancer Chemother Pharmacol. 2015 Oct;76(4):739-50. doi: 10.1007/s00280-015-2826-4. Epub 2015 Aug 8.

PMID:
26254023
11.

A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.

Rimawi MF, Aleixo SB, Rozas AA, Nunes de Matos Neto J, Caleffi M, Figueira AC, Souza SC, Reiriz AB, Gutierrez C, Arantes H, Uttenreuther-Fischer MM, Solca F, Osborne CK.

Clin Breast Cancer. 2015 Apr;15(2):101-9. doi: 10.1016/j.clbc.2014.11.004. Epub 2014 Nov 15.

PMID:
25537159
12.

Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer.

Ring A, Wheatley D, Hatcher H, Laing R, Plummer R, Uttenreuther-Fischer M, Temple G, Pelling K, Schnell D.

Clin Cancer Res. 2015 Jun 15;21(12):2737-44. doi: 10.1158/1078-0432.CCR-14-1812. Epub 2014 Nov 4.

13.

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.

Schnell D, Buschke S, Fuchs H, Gansser D, Goeldner RG, Uttenreuther-Fischer M, Stopfer P, Wind S, Petersen-Sylla M, Halabi A, Koenen R.

Cancer Chemother Pharmacol. 2014 Aug;74(2):267-75. doi: 10.1007/s00280-014-2484-y. Epub 2014 Jun 7.

14.

Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors.

Molife LR, Rudman SM, Alam S, Tan DS, Kristeleit H, Middleton G, Propper D, Bent L, Stopfer P, Uttenreuther-Fischer M, Wallenstein G, de Bono J, Spicer J.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1213-22. doi: 10.1007/s00280-013-2286-7. Epub 2013 Oct 2.

PMID:
24085260
15.

Diarrhea associated with afatinib: an oral ErbB family blocker.

Yang JC, Reguart N, Barinoff J, Köhler J, Uttenreuther-Fischer M, Stammberger U, O'Brien D, Wolf J, Cohen EE.

Expert Rev Anticancer Ther. 2013 Jun;13(6):729-36. doi: 10.1586/era.13.31. Epub 2013 Mar 18. Review.

PMID:
23506556
16.

Dermatologic adverse events associated with afatinib: an oral ErbB family blocker.

Lacouture ME, Schadendorf D, Chu CY, Uttenreuther-Fischer M, Stammberger U, O'Brien D, Hauschild A.

Expert Rev Anticancer Ther. 2013 Jun;13(6):721-8. doi: 10.1586/era.13.30. Epub 2013 Mar 18. Review.

PMID:
23506519
17.

Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer.

Marshall J, Shapiro GI, Uttenreuther-Fischer M, Ould-Kaci M, Stopfer P, Gordon MS.

Future Oncol. 2013 Feb;9(2):271-81. doi: 10.2217/fon.12.195.

18.

A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors.

Gordon MS, Mendelson DS, Gross M, Uttenreuther-Fischer M, Ould-Kaci M, Zhao Y, Stopfer P, Agus DB.

Invest New Drugs. 2013 Apr;31(2):409-16. doi: 10.1007/s10637-012-9904-9. Epub 2012 Dec 15.

19.

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors.

Marshall J, Hwang J, Eskens FA, Burger H, Malik S, Uttenreuther-Fischer M, Stopfer P, Ould-Kaci M, Cohen RB, Lewis NL.

Invest New Drugs. 2013 Apr;31(2):399-408. doi: 10.1007/s10637-012-9890-y. Epub 2012 Nov 17.

20.

Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.

Awada AH, Dumez H, Hendlisz A, Wolter P, Besse-Hammer T, Uttenreuther-Fischer M, Stopfer P, Fleischer F, Piccart M, Schöffski P.

Invest New Drugs. 2013 Jun;31(3):734-41. doi: 10.1007/s10637-012-9880-0. Epub 2012 Nov 17.

21.

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.

Schuler M, Awada A, Harter P, Canon JL, Possinger K, Schmidt M, De Grève J, Neven P, Dirix L, Jonat W, Beckmann MW, Schütte J, Fasching PA, Gottschalk N, Besse-Hammer T, Fleischer F, Wind S, Uttenreuther-Fischer M, Piccart M, Harbeck N.

Breast Cancer Res Treat. 2012 Aug;134(3):1149-59. doi: 10.1007/s10549-012-2126-1. Epub 2012 Jul 5.

22.

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.

Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia AA, Cleator S, Uttenreuther-Fischer M, Jones H, Wind S, Vinisko R, Hickish T.

Breast Cancer Res Treat. 2012 Jun;133(3):1057-65. doi: 10.1007/s10549-012-2003-y. Epub 2012 Mar 15.

23.

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.

Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono JS, Plummer R.

J Clin Oncol. 2010 Sep 1;28(25):3965-72. doi: 10.1200/JCO.2009.26.7278. Epub 2010 Aug 2.

PMID:
20679611
24.

Molecular characterization of the anti-idiotypic immune response of a relapse-free neuroblastoma patient following antibody therapy: a possible vaccine against tumors of neuroectodermal origin?

Uttenreuther-Fischer MM, Krüger JA, Fischer P.

J Immunol. 2006 Jun 15;176(12):7775-86. Erratum in: J Immunol. 2006 Aug 15;177(4):2728.

26.

Restricted VH3 gene usage in phage-displayed Fab that are selected by intravenous immunoglobulin.

Osei A, Uttenreuther-Fischer MM, Lerch H, Gaedicke G, Fischer P.

Arthritis Rheum. 2000 Dec;43(12):2722-32.

27.
28.

Platelet-reactive IgG antibodies cloned by phage display and panning with IVIG from three patients with autoimmune thrombocytopenia.

Fischer P, Jendreyko N, Hoffmann M, Lerch H, Uttenreuther-Fischer MM, Chen PP, Gaedicke G.

Br J Haematol. 1999 Jun;105(3):626-40.

PMID:
10354123
29.

Genetic origin of IgG antibodies cloned by phage display and anti-idiotypic panning from three patients with autoimmune thrombocytopenia.

Jendreyko N, Uttenreuther-Fischer MM, Lerch H, Gaedicke G, Fischer P.

Eur J Immunol. 1998 Dec;28(12):4236-47.

30.

Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

Yu AL, Uttenreuther-Fischer MM, Huang CS, Tsui CC, Gillies SD, Reisfeld RA, Kung FH.

J Clin Oncol. 1998 Jun;16(6):2169-80.

PMID:
9626218
31.

Paediatric thrombo-embolism: the influence of non-genetic factors and the role of activated protein C resistance and protein C deficiency.

Uttenreuther-Fischer MM, Vetter B, Hellmann C, Otting U, Ziemer S, Hausdorf G, Gaedicke G, Kulozik AE.

Eur J Pediatr. 1997 Apr;156(4):277-81.

PMID:
9128811
32.
33.

Resistance to activated protein C (APCR): reference values of APC-ratios for children.

Uttenreuther-Fischer MM, Ziemer S, Gaedicke G.

Thromb Haemost. 1996 Nov;76(5):813-4. No abstract available.

PMID:
8950795
34.

Kawasaki disease: update on diagnosis, treatment, and a still controversial etiology.

Fischer P, Uttenreuther-Fischer MM, Naoe S, Gaedicke G.

Pediatr Hematol Oncol. 1996 Nov-Dec;13(6):487-501. Review.

PMID:
8940732
35.

Superantigens in the aetiology of Kawasaki disease.

Fischer P, Uttenreuther-Fischer MM, Gaedicke G.

Lancet. 1996 Jul 20;348(9021):202. No abstract available.

PMID:
8684184
36.

Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients.

Uttenreuther-Fischer MM, Huang CS, Yu AL.

Cancer Immunol Immunother. 1995 Dec;41(6):331-8.

PMID:
8635190
37.

Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients.

Uttenreuther-Fischer MM, Huang CS, Reisfeld RA, Yu AL.

Cancer Immunol Immunother. 1995 Jul;41(1):29-36.

PMID:
7641217

Supplemental Content

Loading ...
Support Center